Phone: +44 (0)20 7554 5852

AQIX Ltd

The Team


Dr Rees became an Elected Member of the New York Academy of Sciences in 1981 for research studies published (1972-4) on motor nerve terminal metabolism during his Rockefeller Post-Doctoral Fellowship at the University of California (1970-73). In 1973-78 he was appointed Muscular Dystrophy Research Fellow, tenable in the Institute of Neurology, Southern General Hospital, Glasgow, where the development of AQIX® RS-I was initiated using human cadaver nerve-muscle tissue biopsies. In 1978 he was appointed Senior Lecturer in Neurophysiology, Wellington Clinical School and Victoria University, New Zealand. He became Head of Research & Development and Consultant Physiologist of Res-Del Ltd, New Zealand (1980), and implemented his research into the preservation of human organs for transplant based upon his knowledge and internationally published research papers in physiology, neurophysiology, pharmacology and biotechnology. His contribution to organ preservation research over two decades and appointment as Patron of the New Zealand Muscular Dystrophy Association in 1988, led to his election as a Member of the Royal Society of New Zealand in 1997. He was appointed visiting Senior Research Fellow at King's College in the Department of Cardiac Surgical Research, and the Rayne Institute, London, where he has collaborated in the publication of a preclinical study using AQIX® RS-C, a cardioplegic variation of AQIX® RS-I . His research led him to invent the means of keeping animal and human organs alive outside of the body which culminated in the patented design of the Res-Del® Isolated Tissue/Organ Perfusion System (1980) and the development of the AQIX® RS-I Preservation and Perfusion medium, which he went on to successfully patent (2000) and commercially manufacture to GMP standards in 2010.

Martin Powell is a qualified accountant with a wide experience of commercialising start-up companies spun out from universities, in particular, Imperial College, Kings College and Queen Mary University. He performs the finance and administration functions for deltaDOT Ltd and has done so previously for Apatech (bone graft substitute now sold to Baxters) and OSspray (dental powders for hygienists now sold to Denfotex). Previous experience was as financial controller/service company director with a branch of GDF Suez (international mining) and Interval International (travel). He holds a translators degree in French and German from Heidelberg University and is Finance Director of the governing body for the sport Eton Fives and Company Secretary to Perfect Pitch Marquees Ltd (started 2009). He is an associate member of the Association of Corporate Treasurers.

Dr. Masood has spent the last 13 years in drug discovery and then taking novel investigational medicinal products through pre-clinical and clinical development. As a medicinal chemist at Millennium Pharmaceuticals and latterly at Pfizer, he was a member of project teams that discovered MLN4924 (Phase 2 for Oncology) and PF- 389378 (Phase 1 for allergic Rhinitus). He also worked in the chemical technologies group at Pfizer where he evaluated new technologies and approaches in drug discovery. He then moved into drug development and worked in the Regulatory affairs department at Pfizer and more recently at GSK.

Professor Michael Mythen Medical is a Professor of Anaesthesia and Critical Care at UCL; Honorary Consultant Anaesthesia and Critical Care UCL Hospitals (UCLH) NHS Foundation Trust; Director, Centre for Anaesthesia UCL; Director of Research and Development UCLH NHS Foundation Trust; Director Joint UCLH/UCL Biomedical Research Unit; National Clinical Lead Enhanced Recovery Partnership Programme, UK Department of Health; Board Member of the Faculty of Intensive Care Medicine; Chair of the Intensive Care Foundation's Scientific Advisory Board; Chair of the Improving Surgical Outcomes Group; Editorial board member for The British Journal of Anaesthesia, Critical Care; Co-Chairman Evidence Based Peri-operative Medicine (EBPOM) annual meeting and website; Board Member, National Institute Academic Anaesthesia; Examiner for European Diploma of Intensive Care Medicine. Professor Michael (Monty) Mythen completed his UK anaesthesia fellowship (FRCA) in 1990, gained an MD in 1995 and was appointed assistant professor at Duke University Medical Centre, North Carolina, USA before returning to the UK. He has a wide range of research interests including: peri-operative fluid management and trans-oesophageal Doppler, haemostasis in the critically ill, endotoxin and endotoxin immunity and the determinants of post-operative morbidity and mortality. He has over 100 publications on PubMed and has extensive editorial involvement with a number of anaesthetic and critical care journals.